



HAL
open science

Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents

Hubert Blain, Edouard Tuillon, Lucie Gamon, Amandine Pisoni, Stéphanie Miot, Marie-Christine Picot

► **To cite this version:**

Hubert Blain, Edouard Tuillon, Lucie Gamon, Amandine Pisoni, Stéphanie Miot, et al.. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. *Journal of the American Medical Directors Association*, 2022, 23 (5), pp.750 - 753. 10.1016/j.jamda.2022.02.006 . hal-03760314

HAL Id: hal-03760314

<https://hal.science/hal-03760314>

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Strong decay of SARS-CoV-2 spike antibodies after two BNT162b2 vaccine doses and high antibody response to a third dose in nursing home residents

Hubert Blain* MD.PhD, Edouard Tuillon* MD.PhD, Lucie Gamon, Amandine Pisoni, Stéphanie Miot MD.PhD, Marie-Christine Picot MD.PhD

* Hubert Blain and Edouard Tuillon contributed equally to this study.

Authors Affiliations: Department of Internal Medicine and Geriatrics, MUSE University, Montpellier (Blain, Miot); INSERM U 1058/EFS, University hospital, Montpellier (Tuillon, Pisoni); Clinical research and epidemiology unit, University hospital, Montpellier (Gamon, Picot)

Corresponding Author: Prof. Hubert BLAIN, MD.PhD, Pôle de Gériatrie, CHU de Montpellier, 39 avenue Charles Flahault, 34295 Montpellier Cedex 5 (France) (h-blain@chu-montpellier.fr).

Running title : Strong boost vaccine antibody response in residents

Key words: BNT162b2 vaccine; SARS-CoV-2 spike antibodies; nursing home residents; boost vaccine dose.

Funding: This research did not receive any funding from agencies in the public, commercial, or not-for-profit sectors.

Word count: main text: 758 words. **References:** 11. **Graphics count:** 1 table, 1 figure.

Conflicts of interest/Competing interests: Authors declare no conflicts of interest/Competing interests.

Brief summary - The 6-month post-vaccine decay of antibodies and the high antibody response after the third BNT162b2 vaccine dose validate a boost vaccine dose less than 6 months after the second dose in residents.

Authors' contributions: Hubert Blain has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Design and conduct of the study: Blain, Tuaillon

Collection, management, analysis, and interpretation of the data: all authors

Drafting of the manuscript: Blain, Tuaillon

Critical revision of the manuscript: all authors

Decision to submit the manuscript for publication: Blain

Acknowledgements: The authors would like to thank (i) Jean Bousquet for the interpretation of data, (ii) Anna Bedbrook and Fabienne Portejoie for editorial assistance, (iii) Secours Infirmiers (Department of Geriatrics, Montpellier University Hospital), Florence Biblocque and Maxime Douville (admission office, Montpellier University Hospital) for material support, and (iv) the residents and staff members of the nursing homes involved in the study. None of these contributors received any compensation for their help in carrying out the study.

1 **Abstract**

2 **Objectives:** To measure the antibody decay after two BNT162b2 doses and the antibody
3 response after a third vaccine dose administered 6 months after the second one in nursing home
4 residents with and without prior COVID-19.

5 **Design:** Cohort study.

6 **Setting and Participants:** 418 residents from 18 nursing homes.

7 **Methods:** Blood RBD-IgG (IgG II Quant assay, Abbott Diagnostics; upper limit: 5680 BAU)
8 and nucleocapsid-IgG (Abbott Alinity) were measured 21-28 days after the second BNT162b2
9 dose, as well as 1-3 days before and 21-28 days after the third vaccine dose. RBD-IgG levels \geq
10 592 BAU/mL were considered as high antibody response. Residents with prior positive RT-
11 qPCR on a nasopharyngeal swab or with N-IgG levels above 0.8 S/CO were considered as prior
12 COVID-19 residents.

13 **Results:** In prior COVID-19 residents (n=122), RBD-IgG median levels decreased by 82% in
14 167 days on average. In the same period, the number of residents with a high antibody response
15 decreased from 88.5% to 54.9% ($p < .0001$) and increased to 97.5% after the third vaccine dose
16 ($p = 0.02$ vs the first measure). In residents without prior COVID-19 (n=296), RBD-IgG median
17 levels decreased by 89% in 171 days on average. The number of residents with a high antibody
18 response decreased from 29.4 to 1.7% ($p < .0001$) and increased to 88.4% after the third vaccine
19 dose ($p < .0001$ vs the first measure)

20 **Conclusions and Implications:** The strong and rapid decay of RBD-IgG levels after the second
21 BNT162b2 dose in all residents and the high antibody response after the third dose validate the
22 recommendation of a third vaccine dose in residents less than 6 months after the second dose,
23 prioritizing residents without prior COVID-19. The slope of RBD-IgG decay after the third

24 BNT162b2 dose and the protection level against SARS-CoV-2 B.1.1.529 (omicron) and other
25 variants of concern provided by the high post-boost vaccination RBD-IgG response require
26 further investigation in residents.
27

28 **Introduction**

29 Nursing home (NH) residents are at high risk for severe COVID-19. Vaccination using the
30 mRNA COVID-19 vaccine is safe and effective in adults but is less documented in older
31 persons.¹⁻³ The humoral response observed in NH residents 21 days after the first BNT162b2
32 vaccine dose⁴, and 14 days^{5,6} and 6 months following the second vaccine dose,⁷⁻⁹ has been
33 shown to be lower than that observed in healthcare professionals. In addition, outbreaks of the
34 SARS-CoV-2 variants B.1.1. 4-7 (alpha) and B.1.617.2 (delta) have been reported in nursing
35 homes (NHs) less than 6 months after the full BNT162b2 vaccination of most residents.^{8,11} The
36 low humoral response observed after two BNT162b2 doses, associated with reduced vaccine
37 protection some months after the second vaccine dose, has led to recommendations in the US and
38 in other countries such as France of an additional vaccine dose at least 5 months after the second
39 vaccine dose in persons moderately or severely immunocompromised.^{12,13} In France, more than
40 95% of residents had received a second BNT162b2 dose in September 2021.¹⁴
41 The 6-month post-vaccine antibody decay after the second vaccine dose and the antibody
42 response to the third dose have not been quantified in the same NH residents, which does not
43 enable the comparison of the antibody response after 2 and 3 BNT162b2 doses.
44 We compared IgG levels against the SARS-CoV-2 Receptor-Binding Domain (RBD-IgG) (i)
45 after two doses of BNT162b2, (ii) just before the third vaccine dose, and (iii) after the third dose.
46 We distinguished those with and without prior COVID-19.

47 **Methods**

48 Since March 2019, around 6,000 residents from 122 nursing homes are being prospectively
49 followed in the Montpellier area (French Occitanie region). All residents, with or without prior
50 COVID-19 (outbreaks of wild type SARS-CoV-2 between March 2020 and February 2021; of

51 SARS-CoV-2 B.1.1.7 between February 2021 and October 2021; of B.1.617.2 between July
52 2021 and October 2021), were offered two vaccine doses in January-February 2021, and a third
53 dose 6 months later. A follow-up of post-vaccine antibody response was proposed in residents
54 from fifteen nursing homes having faced a COVID-19 outbreak in 2020. Blood testing was
55 performed 21-28 days after the second vaccine dose, as well as 1-3 days before and 21-28 days
56 after the third dose, to assess RBD-IgG (IgG II Quant assay, Abbott Diagnostics; upper limit:
57 5680 BAU) and nucleocapsid-IgG (Abbott Alinity). RBD-IgG levels < 149 BAU/mL or ≥ 592
58 BAU/mL were considered as low or high responses, respectively.^{15,16} Residents with a history of
59 positive RT-qPCR on a nasopharyngeal swab or with N-IgG levels above 0.8 S/CO were
60 considered as prior COVID-19 residents. All participants (or their legal representative) provided
61 informed consent. The study was approved by our University Hospital institutional review board.
62 RBD-IgG levels were compared by using the Friedman and Cochran tests, and the multinomial
63 mixed model for repeated measures. The statistical significance threshold was set at 5%.
64 Analyses were performed using the SAS Enterprise Guide, v7.3 (SAS Institute Inc).

65 **Results**

66 The characteristics of the residents included in the 15 nursing homes are shown in Table 1. Of
67 the 418 studied residents, 296 had no previous COVID-19 infection (mean age 88 ± 8 years, 74%
68 women), and 122 had prior COVID-19 (88.6 ± 8 years, 81% women). The mean lapse of time
69 between the first and the second RBD-IgG measures were 171 ± 11 and 167 ± 11 days,
70 respectively.

71 In prior COVID-19 residents, RBD-IgG median levels decreased by 82% between the first and
72 second measures (4,318 BAU/mL to 773 BAU/mL), and the number of residents with a high

73 antibody response decreased from 88.5% to 54.9% ($p < .0001$). After the third dose, RBD-IgG
74 median levels increased significantly (to 3,596 BAU/mL), and the number of residents with a
75 high RBD-IgG level was higher after the third and after the second dose (97.5% vs 88.5%,
76 respectively)($p = 0.02$)(Table 2, Figure).

77 In residents without prior COVID-19, RBD-IgG median levels between the first and second
78 measures decreased by 89% (348 BAU/mL to 35 BAU/mL), and the number of residents with a
79 high antibody response decreased from 29.4% to 1.7% ($p < .0001$). After the third vaccine dose,
80 88.4% of residents had a high antibody response vs 29.4% after the second dose, and 4.7% had a
81 low antibody response vs 27.4% ($p < .0001$)(Table, Figure).

82

83 **Discussion**

84 This preliminary study shows that 6 months after the second BNT162b2 dose, 88.8% of residents
85 without prior COVID-19 have an RBD-IgG level below 149 BAU, and only 54.9% of those with
86 prior COVID-19 have an RBD-IgG level above 592 BAU. The 82-89% decrease in RBD-IgG
87 level observed in both groups in less than 6 months may partly explain the occurrence of
88 outbreaks of the SARS-CoV-2 variants B.1.1. 4-7 and, more recently, of the Delta variant
89 B.1.617.2 in nursing homes (NHs) in which most of the residents had been vaccinated with two
90 doses of the BNT162b2 vaccine.^{8,11} This tends to validate, on an immunological basis, the
91 recommendation of a third BNT162b2 dose at least 5 months after the second one in NH
92 residents. The RBD-IgG response after 3 vaccine doses is significantly higher than that observed
93 after two doses, and is excellent, largely above 592 BAU, in 97.5% of the residents with prior
94 COVID-19 and in 88.4% of those without. Limitations of the study include the relatively small

95 sample size, with a possible lack of representativeness, and the lack of clinical data in residents
96 with prior COVID-19. Whether the severity of the initial infection has impacted the antibody
97 response to the vaccine cannot be analyzed in this study. One other limitation is the lack of
98 neutralization assays. However, we used an automated quantitative assay to measure the RBD
99 IgG level that correlates well with virus neutralization.^{17,18} We did not assess T-cell contribution
100 to vaccine-induced immunity. The present study focuses on antibodies and not on clinical
101 disease. Even if associations have been shown between RBD-IgG levels and protection against
102 SARS-CoV-2 in healthcare workers and NH residents^{8,11, 19-21}, whether the high level of RBD
103 IgG found after a booster BNT162b2 dose in most residents is associated with high protection
104 against COVID-19 remains to be determined.

105 Because the administration of a booster BNT162b2 dose as well as the vaccination of previously
106 infected individuals generate an anti-B.1.1.529 neutralizing response, with titers 5 to 31 fold
107 lower against Omicron than against Delta,²² further studies are needed to assess whether the high
108 RBD-IgG response found in most of the residents after the third vaccine dose will be sufficient to
109 prevent SARS-CoV-2 B.1.1.529 in those with and without prior COVID-19 and, if so, for what
110 duration.

111 **Conclusions and Implications**

112 The strong and rapid decay of RBD-IgG levels 6 months after the second BNT162b2 dose
113 observed in most of the residents (with very low levels observed after the second dose in
114 residents without prior COVID-19), as well as the high antibody response after the third dose in
115 the residents (observed in the present study and in a recent unpublished study)²³ support, on an
116 immunological basis, the recommendation to offer a third vaccine dose in nursing home residents
117 less than at least 5 months after the second dose, prioritizing those without prior COVID-19.

118 Whether the slope of RBD-IgG decay after the third BNT162b2 dose will be similar to that
119 found after the second vaccine dose, and whether the high RBD-IgG response found after the
120 third vaccine dose will be associated with a high protection level against SARS-CoV-2 B.1.1.529
121 and other variants of concern require further investigation in nursing home residents.

122

123

124 **Figure.** Individual change in RBD-IgG levels between 21-28 days after the second BNT162b2
125 vaccine dose (Post-V2), 1-3 days before the third vaccine dose (Pre-V3), and 21-28 after the
126 third vaccine dose (Post-V3) of residents with or without confirmed prior COVID-19

127 **Legend:** Between March 2019 and September 2021, residents from nursing homes facing a
128 COVID-19 outbreak had repeated RT-qPCR testing until no new cases were diagnosed.
129 Residents from 18 nursing homes having faced a COVID-19 outbreak in 2020 were proposed to
130 undergo blood testing (i) to follow their post-BNT162b2 vaccine response using SARS-CoV-2
131 Receptor-Binding Domain (RBD-IgG) levels (IgG II Quant assay, Abbott Diagnostics; upper
132 limit: 5680 BAU) and (ii) to determine if they had prior COVID-19, using IgG antibodies against
133 the SARS-CoV-2 nucleocapsid protein (N Protein-IgG) (Abbott Alinity; positive level when
134 above 0.8 S/CO). Blood testing when an informed consent was obtained was performed 21-28
135 days after the second vaccine dose, 1-3 days before the third dose, and 21-28 days after the third
136 dose in order to make comparisons possible in every resident. To make the illustration more
137 readable, the change in values of RBD-IgG levels 21-28 days after the second vaccine dose,
138 before the third dose administered 6 months after the second dose, and 21-28 days after the third
139 vaccine dose are presented for 100 residents with and 100 residents without prior COVID-19.

140 These residents were drawn at random from the 122 with and the 296 without confirmed prior
141 COVID-19.

142 References

- 143 1. Benin AL, Soe MM, Edwards JR, et al. Ecological Analysis of the Decline in Incidence
144 Rates of COVID-19 among Nursing Home Residents Associated with Vaccination,
145 United States, December 2020-January 2021. *J Am Med Dir Assoc.* 2021;22:2009-2015.
146 doi: 10.1016/j.jamda.2021.08.004.
- 147 2. Cabezas C, Coma E, Mora-Fernandez N, et al. Associations of BNT162b2 vaccination
148 with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing
149 homes and healthcare workers in Catalonia: prospective cohort study. *BMJ.*
150 2021;374:n1868.
- 151 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
152 Covid-19 Vaccine. *N Engl J Med.* 2020;383:2603-2615.
- 153 4. Blain H, Tuaille E, Gamon L, Pisoni A, Miot S, Picot MC, Bousquet J. Spike Antibody
154 Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a
155 Single BNT162b2 Vaccine Dose. *JAMA.* 2021;325:1898-1899. doi:
156 10.1001/jama.2021.6042.
- 157 5. Canaday DH, Carias L, Oyebanji OA, et al. Reduced BNT162b2 Messenger RNA
158 Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
159 2)-Naive Nursing Home Residents. *Clin Infect Dis.* 2021;73:2112-2115. doi:
160 10.1093/cid/ciab447.
- 161 6. Blain H, Tuaille E, Gamon L, et al. Antibody response after one and two jabs of the
162 BNT162b2 vaccine in nursing home residents: The CONsort-19 study. *Allergy.*
163 2022;77:271-281. doi: 10.1111/all.15007.
- 164 7. Salmerón Ríos S, Cortés Zamora EB, Avendaño Céspedes A, et al. Immunogenicity after
165 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The
166 COVID-A Study. *J Am Geriatr Soc.* 2021. doi: 10.1111/jgs.17620.
- 167 8. Pierobon A, Zotto AD, Antico A, et al. Outbreak of SARS-CoV-2 B.1.617.2 (delta)
168 variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines:
169 evidence of a waning immunity. *Clin Microbiol Infect.* 2021:S1198-743X(21)00721-7.
170 doi: 10.1016/j.cmi.2021.12.013.
- 171 9. Canaday DH, Oyebanji OA, Keresztesy D, et al. Significant reduction in vaccine-induced
172 antibody levels and neutralization activity among healthcare workers and nursing home
173 residents 6 months following COVID-19 BNT162b2 mRNA vaccination. *Clinical*
174 *Infectious Diseases.* 2021., ciab963, <https://doi.org/10.1093/cid/ciab963>
- 175 10. Burugorri-Pierre C, Lafuente-Lafuente C, Oasi C, et al. Investigation of an Outbreak of
176 COVID-19 in a French Nursing Home With Most Residents Vaccinated. *JAMA Netw*
177 *Open.* 2021;4:e2125294. doi: 10.1001/jamanetworkopen.2021.25294.
- 178 11. Blain H, Tuaille E, Gamon L, et al. Receptor binding domain-IgG levels correlate with
179 protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. *Allergy.* 2021. doi:
180 10.1111/all.15142.

- 181 12. Hall E. Updates to Interim Clinical Considerations for Use of COVID19 Vaccines
182 Advisory Committee on Immunization Practices Meeting. February 4, 2022
183 [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-04/08-COVID-
185 Hall-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-04/08-COVID-
184 Hall-508.pdf)
186 13. Covid-19 : la Haute Autorité de Santé précise les populations éligibles à une dose de
187 rappel de vaccin [https://www.has-sante.fr/jcms/p_3283153/fr/covid-19-la-has-precise-
189 les-populations-eligibles-a-une-dose-de-rappel-de-vaccin](https://www.has-sante.fr/jcms/p_3283153/fr/covid-19-la-has-precise-
188 les-populations-eligibles-a-une-dose-de-rappel-de-vaccin)
190 14. Le tableau de bord de la vaccination en France. [https://solidarites-sante.gouv.fr/grands-
192 dossiers/vaccin-covid-19/article/le-tableau-de-bord-de-la-vaccination](https://solidarites-sante.gouv.fr/grands-
191 dossiers/vaccin-covid-19/article/le-tableau-de-bord-de-la-vaccination)
193 15. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
194 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.*
195 2021;27:1205-1211. doi: 10.1038/s41591-021-01377-8.
196 16. Van Praet JT, Vandecasteele S, De Roo A, et al. Humoral and cellular immunogenicity of
197 the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents. *Clin Infect Dis.*
198 2021:ciab300. doi: 10.1093/cid/ciab300.
199 17. Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti-SARS-CoV-2
200 spike protein ectodomain and receptor-binding domain IgG correlate with virus
201 neutralization. *J Clin Invest.* 2020 Dec 1;130(12):6728-6738. doi: 10.1172/JCI141206.
202 18. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-
203 CoV-2 and circulating variants. *Nature.* 2021;592(7855):616-622. doi: 10.1038/s41586-
204 021-03324-6.
205 19. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated
206 Health Care Workers. *N Engl J Med.* 2021;385(16):1474-1484
207 20. Feng S, Phillips DJ, White T, et al. Oxford COVID Vaccine Trial Group. Correlates of
208 protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med.*
209 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1.
210 21. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune Assays Team; Moderna, Inc.
211 Team; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy
212 (COVE) Team§; United States Government (USG)/CoVPN Biostatistics Team§. Immune
213 correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science.*
214 2022;375:43-50. doi: 10.1126/science.abm3425.
215 22. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to
216 antibody neutralization. *Nature.* 2021. doi: 10.1038/s41586-021-04389-z.
23. Canaday DH, Oyebanji OA, White E, et al. Significantly elevated antibody levels and
neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA
booster vaccination. *medRxiv.* 2021. doi: 10.1101/2021.12.07.21267179.

Nursing homes	Studied residents, N (%)	Female/male gender, N (%)	Age, Mean (SD)	Prior COVID-19, N (%)
1	38 (9.1)	28 (73.7)/ 10 (26.3)	86.5 (8.7)	9 (23.7)
2	38 (9.1)	34 (89.5)/ 4 (10.5)	92.1 (5.6)	15 (39.5)
3	37 (8.8)	27 (73.0)/ 10 (27.0)	86.4 (8.4)	4 (10.8)
4	14 (3.3)	10 (71.4)/ 4 (28.6)	83.1 (10.6)	2 (14.3)
5	25 (6.0)	17 (68.0)/ 8 (32.0)	84.6 (7.4)	10 (40.0)
6	28 (6.7)	19 (67.9)/ 9 (32.1)	86.8 (7.0)	8 (28.6)
7	26 (6.2)	20 (76.9)/ 6 (23.1)	87.0 (6.8)	7 (26.9)
8	21 (5.0)	15 (71.4)/ 6 (28.6)	86.7 (8.7)	6 (28.6)
9	32 (7.7)	23 (71.9)/ 9 (28.1)	86.6 (7.7)	9 (28.1)
10	34 (8.1)	28 (82.3)/ 6 (17.7)	91.2 (7.3)	26 (76.5)
11	11 (2.6)	10 (90.9)/ 1 (9.1)	92.8 (5.4)	3 (27.3)
12	20 (4.8)	15 (75.0)/ 5 (25.0)	91.9 (7.2)	9 (45.0)
13	27 (6.5)	21 (77.8)/ 6 (22.2)	87.1 (8.8)	6 (22.2)
14	37 (8.8)	27 (73.0)/ 10 (27.0)	90.4 (5.6)	8 (21.6)
15	30 (7.2)	23 (76.7)/ 7 (23.3)	89.3 (8.2)	0 (0.0)
Total	418 (100)	317 (75.8)/ 101 (24.2)	88.7 (8.0)	122 (29.2)

217
218
219


Table 1. Demographic characteristics of the residents studied in 15 nursing homes

220 Table 2: RBD-IgG levels 4-5 weeks after the second BNT162b2 vaccine dose (A), 1-3 days
 221 before the third vaccine dose (B), and 4-5 weeks after the third vaccine dose (C) of residents with
 222 (n=122) or without (n = 296) confirmed prior COVID-19 infection.
 223

	After the second vaccine dose (A)	Before the third vaccine dose (B)	After the third vaccine dose (C)	P value
Prior COVID-19 residents (n=122)				<.0001
RBD IgG level, median (IQRs), BAU	4318 (1772 ; 5680)	773 (339 ; 1742)	3596 (1751 ; 5680)	
RBD IgG Level, No. (%)				<.0001 ^b
- < 149 BAU	5 (4.1)	16 (13.1)	0	<.001 ^c A vs B
- 150 - 591 BAU	9 (7.4)	39 (32.0)	3 (2.5)	and B vs C
- ≥ 592 BAU	108 (88.5)	67 (54.9)	119 (97.5)	.02 ^c A vs C
Without Prior COVID-19 residents (n=296)				<.0001
RBD IgG level, median (IQRs), BAU	348 (120 ; 752)	35 (15 ; 70)	1926 (875 ; 3866)	
RBD IgG Level, No. (%)				<.0001 ^b
- < 149 BAU	81 (27.4)	263 (88.8)	14 (4.7)	<.0001 ^c A vs B,
- 150 - 591 BAU	128 (43.2)	28 (9.5)	41 (13.8)	B vs C, and A vs C
- ≥ 592 BAU	87 (29.4)	5 (1.7)	241 (88.4)	

224
 225 ^a Friedman test; ^b Multinomial mixed model; ^c Cochran test

Prior-COVID-19



Without prior COVID-19

